Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyAzapropazone
Identification
- Name
- Azapropazone
- Accession Number
- DB07402
- Type
- Small Molecule
- Groups
- Withdrawn
- Description
- Not Available
- Structure
- Synonyms
- azapropazona
- Azapropazone
- International/Other Brands
- Rheumox (Amdipharm Mercury Company Limited)
- Categories
- Agents causing hyperkalemia
- Agents that produce hypertension
- Analgesics
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Antigout Preparations
- Antiinflammatory and Antirheumatic Products
- Antiinflammatory and Antirheumatic Products, Non-Steroids
- Central Nervous System Agents
- Musculo-Skeletal System
- Nephrotoxic agents
- Peripheral Nervous System Agents
- Renal Agents
- Sensory System Agents
- Triazines
- Uricosuric Agents
- UNII
- K2VOT966ZI
- CAS number
- 13539-59-8
- Weight
- Average: 298.3397
Monoisotopic: 298.14297584 - Chemical Formula
- C16H18N4O2
- InChI Key
- WOIIIUDZSOLAIW-NSHDSACASA-N
- InChI
- InChI=1S/C16H18N4O2/c1-5-6-11-14(21)19-13-9-10(2)7-8-12(13)17-16(18(3)4)20(19)15(11)22/h5,7-9,11H,1,6H2,2-4H3/t11-/m0/s1
- IUPAC Name
- (4S)-7-(dimethylamino)-12-methyl-4-(prop-2-en-1-yl)-2,6,8-triazatricyclo[7.4.0.0²,⁶]trideca-1(13),7,9,11-tetraene-3,5-dione
- SMILES
- [H][C@@]1(CC=C)C(=O)N2N(C1=O)C1=CC(C)=CC=C1N=C2N(C)C
Pharmacology
- Indication
- Not Available
- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half life
- Not Available
- Clearance
- Not Available
- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction (R)-warfarin The risk or severity of bleeding and hemorrhage can be increased when Azapropazone is combined with (R)-warfarin. (S)-Warfarin The risk or severity of bleeding and hemorrhage can be increased when Azapropazone is combined with (S)-Warfarin. 1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic Acid The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Azapropazone is combined with 1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic Acid. 1-benzylimidazole The risk or severity of hypertension can be increased when 1-benzylimidazole is combined with Azapropazone. 2,5-Dimethoxy-4-ethylamphetamine The risk or severity of hypertension can be increased when 2,5-Dimethoxy-4-ethylamphetamine is combined with Azapropazone. 2,5-Dimethoxy-4-ethylthioamphetamine The risk or severity of hypertension can be increased when Azapropazone is combined with 2,5-Dimethoxy-4-ethylthioamphetamine. 3,4-Methylenedioxyamphetamine The risk or severity of hypertension can be increased when 3,4-Methylenedioxyamphetamine is combined with Azapropazone. 4-Bromo-2,5-dimethoxyamphetamine The risk or severity of hypertension can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Azapropazone. 4-hydroxycoumarin The risk or severity of bleeding and hemorrhage can be increased when Azapropazone is combined with 4-hydroxycoumarin. 4-Methoxyamphetamine The risk or severity of hypertension can be increased when 4-Methoxyamphetamine is combined with Azapropazone. - Food Interactions
- Not Available
References
- Synthesis Reference
Molnar, I., Wagner-Jauregg,T., Jahn, U. and Mixich, G.; US. Patent 3,349,088; October 24, 1967; assigned to Siegfried AG, Switzerland Molnar, I.,Wagner-Jauregg,T., Jahn, U. and Mixich, G.; US. Patent 3,482,024; December 2, 1969; assigned to Siegfried AG.
- General References
- Not Available
- External Links
- ATC Codes
- M01AX04 — Azapropazone
- PDB Entries
- 2bx8 / 2bxi / 2bxk
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 187 Molnar, I., Wagner-Jauregg,T., Jahn, U. and Mixich, G.; US. Patent 3,349,088; October 24, 1967; assigned to Siegfried AG, Switzerland Molnar, I.,Wagner-Jauregg,T., Jahn, U. and Mixich, G.; US. Patent 3,482,024; December 2, 1969; assigned to Siegfried AG. - Predicted Properties
Property Value Source Water Solubility 0.641 mg/mL ALOGPS logP 0.92 ALOGPS logP 2.08 ChemAxon logS -2.7 ALOGPS pKa (Strongest Acidic) 0.52 ChemAxon pKa (Strongest Basic) 7.58 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 4 ChemAxon Hydrogen Donor Count 0 ChemAxon Polar Surface Area 56.22 Å2 ChemAxon Rotatable Bond Count 2 ChemAxon Refractivity 85.69 m3·mol-1 ChemAxon Polarizability 31.94 Å3 ChemAxon Number of Rings 3 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 1.0 Blood Brain Barrier + 0.9389 Caco-2 permeable + 0.5728 P-glycoprotein substrate Non-substrate 0.5961 P-glycoprotein inhibitor I Inhibitor 0.8281 P-glycoprotein inhibitor II Inhibitor 0.6484 Renal organic cation transporter Non-inhibitor 0.7843 CYP450 2C9 substrate Non-substrate 0.8218 CYP450 2D6 substrate Non-substrate 0.8107 CYP450 3A4 substrate Substrate 0.6289 CYP450 1A2 substrate Inhibitor 0.5528 CYP450 2C9 inhibitor Non-inhibitor 0.8735 CYP450 2D6 inhibitor Non-inhibitor 0.9188 CYP450 2C19 inhibitor Non-inhibitor 0.8614 CYP450 3A4 inhibitor Non-inhibitor 0.8273 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.725 Ames test AMES toxic 0.5466 Carcinogenicity Non-carcinogens 0.8321 Biodegradation Not ready biodegradable 1.0 Rat acute toxicity 2.4784 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.7311 hERG inhibition (predictor II) Non-inhibitor 0.8171
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as aminotriazines. These are organic compounds containing an amino group attached to a triazine ring.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Triazines
- Sub Class
- Aminotriazines
- Direct Parent
- Aminotriazines
- Alternative Parents
- Pyrazolidinones / Benzenoids / 1,3-dicarbonyl compounds / 1,2,4-triazines / Guanidines / Carboxylic acid hydrazides / Propargyl-type 1,3-dipolar organic compounds / Azacyclic compounds / Organopnictogen compounds / Organic oxides show 1 more
- Substituents
- Amino-1,2,4-triazine / Aminotriazine / Pyrazolidinone / 1,3-dicarbonyl compound / Benzenoid / 1,2,4-triazine / Pyrazolidine / Carboxylic acid hydrazide / Guanidine / Azacycle show 12 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
Carriers
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Toxic substance binding
- Specific Function
- Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
- Gene Name
- ALB
- Uniprot ID
- P02768
- Uniprot Name
- Serum albumin
- Molecular Weight
- 69365.94 Da
References
- Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Drug created on September 15, 2010 15:21 / Updated on November 02, 2018 06:32